[Skip to Content]

Upstate Active Clinical Trials

Study Title:

AALL1731 - A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)

What is the purpose of the study? (in Layman's terms, please describe the study)

A Phase 3 Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)

Upstate Institutional Review Board (IRB) Number:

1464114

Study/Protocol ID:

AALL1731

Study Phase:

III

Patient Age Group:

Children

Principal Investigator:

Melanie A Comito

Who is eligible?

Patients must be > 365 days and < 10 years of age (B-ALL patients without DS)
Patients must be > 365 days and ≤ 31 years of age (B-ALL patients with DS)
Patients must be > 365 days and ≤ 31 years of age (B-LLy patients with or without DS)

What is involved if I participate?

  • How long is the study?
    Treatment is 2 years from the start of Interim Maintenance I and then followed on study for 10 years.
  • Is transportation provided or reimbursed?
    No
  • Is parking provided or reimbursed?
    Yes
  • What tests and procedures are involved?
    lab draws, bone marrow aspirate/biopsy, lumbar puncture

Where will the study take place?

Pediatric Cancer Center

Other Information:

N/A

Who can I contact for more information?

Name: Karen B Bilynsky
Phone: 315-464-7601
Email: [email protected]

Return to Previous Page || Search Again

Top